J Thorac Oncol
Lorlatinib Should Not be Considered as the Preferred First-Line Option in Patients With Advanced ALK Rearranged NSCLC.
Related Questions
The CROWN, ALTA, and ALEX trials showed improved efficacy with lorlatinib/brigatinib/alectinib vs crizotinib. How do you choose your first line therap...
New answer by Medical Oncologist at St Lukes Cancer Care Assocs (August 17, 2025)
Alectinib, followed by lorlatinib if there is no CNS involvement. If the patient has CNS involvement, I go straight to lorlatinib. Thanks.